ALN-APP-002: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients with Cerebral Amyloid Angiopathy (CAA)

Grants and Contracts Details

StatusActive
Effective start/end date10/3/24 → 10/3/26

Funding

  • Alnylam Pharmaceuticals Incorporated: $2.00